King B F, Hartman G W, Williamson B, LeRoy A J, Hattery R R
Department of Diagnostic Radiology, Mayo Clinic.
Mayo Clin Proc. 1989 Aug;64(8):976-85. doi: 10.1016/s0025-6196(12)61226-9.
Intravascular radiographic contrast media play a major role in diagnostic imaging. Recently, low-osmolality contrast media (LOCM) have become available in the United States. Because of their lower osmolality, these new agents cause fewer undesirable physiologic effects and fewer adverse reactions than do conventional agents after intravascular administration. Unfortunately, the cost of LOCM is substantially higher than the cost of conventional contrast media. Appropriate use of these newer, more expensive contrast agents must be based on a thorough knowledge and understanding of their chemistry, physiologic features, and relative safety. Some questions remain about these new agents. Further studies are needed to determine the nephrotoxicity of LOCM relative to that of conventional agents. In addition, LOCM have less anticoagulant capacity than do the conventional media; therefore, clotting may occur when the LOCM and blood mix in syringes and small catheters. This potential decrease in anticoagulation and its clinical implications should be further investigated. Finally, the mortality rate associated with use of LOCM needs to be determined in future studies in large numbers of patients.
血管内造影剂在诊断成像中起着重要作用。最近,低渗造影剂(LOCM)在美国已可获得。由于其较低的渗透压,这些新型制剂在血管内给药后比传统制剂引起的不良生理效应和不良反应更少。不幸的是,LOCM的成本远高于传统造影剂。正确使用这些更新的、更昂贵的造影剂必须基于对其化学性质、生理特征和相对安全性的全面了解。关于这些新型制剂仍存在一些问题。需要进一步研究以确定LOCM相对于传统制剂的肾毒性。此外,LOCM的抗凝能力比传统造影剂弱;因此,当LOCM与血液在注射器和小导管中混合时可能会发生凝血。这种抗凝作用的潜在降低及其临床意义应进一步研究。最后,需要在未来对大量患者的研究中确定与使用LOCM相关的死亡率。